MYH14 and sarcopenia: The availability of skeletal-selective myosin activators could have a great impact in the development of treatments for skeletal muscle diseases/myopathies where myosin function is disrupted directly (e.g., mutations in MYH2 (24) or in other sarcomeric proteins interacting with it (25,26)) or indirectly (e.g., sarcopenia (27)).